Neuronetics, Inc.

How big is Neuronetics, Inc.?

As of Jun 18, Neuronetics, Inc. has a market capitalization of 229.71 million and reported net sales of 89.45 million with a net profit of -48.02 million over the latest four quarters.

Market Cap: As of Jun 18, Neuronetics, Inc. has a market capitalization of 229.71 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Neuronetics, Inc. reported net sales of 89.45 million and a net profit of -48.02 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 27.71 million and total assets of 140.90 million.

What does Neuronetics, Inc. do?

Neuronetics, Inc. is a medical technology company that develops devices for treating psychiatric disorders, with a market cap of approximately $229.71 million. As of March 2025, it reported net sales of $32 million and a net loss of $13 million.

Overview:<BR>Neuronetics, Inc. is a commercial-stage medical technology company focused on designing and developing medical devices to treat psychiatric disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 32 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -13 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 229.71 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 1.10 <BR>Return on Equity: -122.96% <BR>Price to Book: 6.48<BR><BR>Contact Details:<BR>Address: 3222 Phoenixville Pike, MALVERN PA: 19355-9615 <BR>Tel: ['1 610 6404202', '61 410 6272087'] <BR>Fax: 1 610 6404206 <BR>Website: http://www.neuronetics.com

Should I buy, sell or hold Neuronetics, Inc.?

Who are in the management team of Neuronetics, Inc.?

As of March 2022, the management team of Neuronetics, Inc. includes Mr. Brian Farley (Independent Non-Executive Chairman), Mr. Keith Sullivan (President and CEO), and Directors Mr. John Bakewell, Ms. Sheryl Conley, Dr. Wilfred Jaeger, and Mr. Glenn Muir. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of Neuronetics, Inc. includes the following individuals:<BR><BR>- Mr. Brian Farley, who serves as the Independent Non-Executive Chairman of the Board.<BR>- Mr. Keith Sullivan, who is the President, Chief Executive Officer, and Director.<BR>- Mr. John Bakewell, who is a Director.<BR>- Ms. Sheryl Conley, who is an Independent Director.<BR>- Dr. Wilfred Jaeger, who is also an Independent Director.<BR>- Mr. Glenn Muir, who serves as an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Is Neuronetics, Inc. overvalued or undervalued?

As of November 6, 2018, Neuronetics, Inc. is considered risky and overvalued due to high Price to Book and EV to Sales ratios, negative returns on equity and capital employed, and a significantly lower P/E ratio compared to peers, indicating struggles in generating shareholder returns.

As of 6 November 2018, the valuation grade for Neuronetics, Inc. has moved from does not qualify to risky, indicating a significant shift in the company's perceived value. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 6.91 and an EV to Sales ratio of 3.17, which suggest that the market is pricing the stock at a premium relative to its underlying assets and sales performance. Additionally, the negative ROE of -122.96% and ROCE of -51.42% further highlight the company's struggles in generating returns for shareholders.<BR><BR>In comparison to its peers, Neuronetics, Inc. has a P/E ratio of -5.1110, which is significantly lower than Delcath Systems, Inc. at 68.0649, indicating a stark contrast in valuation between the two companies. Other risky peers like Eargo, Inc. and Sensus Healthcare, Inc. also show negative P/E ratios, but Neuronetics' valuation metrics suggest it is not positioned favorably within its industry. Although specific return data is not available, the lack of positive returns compared to the S&P 500 reinforces the notion that Neuronetics is currently overvalued.

Is Neuronetics, Inc. technically bullish or bearish?

As of August 11, 2025, Neuronetics, Inc. shows a mildly bullish trend overall, but mixed signals from various indicators suggest caution due to bearish pressures on the weekly metrics.

As of 11 August 2025, the technical trend for Neuronetics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bearish while the monthly MACD is bullish, indicating mixed signals. The daily moving averages are mildly bullish, supporting a positive short-term outlook. However, the weekly Bollinger Bands are bearish and the KST shows a mildly bearish stance on the weekly timeframe, which adds to the cautious sentiment. Dow Theory also reflects a mildly bearish position on both weekly and monthly charts. Overall, the indicators suggest a mildly bullish stance, but with notable bearish pressures in the weekly metrics. There is no available return data to compare the company's performance against the S&P 500.